Lajos Pusztai, MD, DPhil, discusses the promise of circulating tumor DNA assays in breast cancer.
Lajos Pustzai, MD, DPhil
Advertisement
Articles by Lajos Pustzai, MD, DPhil
Lajos Pusztai, MD, DPhil, discusses the role of circulating tumor DNA as a biomarker of response in patients with high-risk early-stage breast cancer.
Lajos Pustzai, MD, DPhil, professor of Medicine (Medical Oncology), chief of Breast Medical Oncology, co-director, Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale Cancer Center, discusses how treatment for patients with HER2-positive breast cancer has evolved.
Advertisement
Latest Updated Articles
Dr. Pusztai on the Promise of ctDNA Assays in Breast CancerDecember 22nd 2020
Dr. Pusztai on the Role of ctDNA as a Biomarker in Breast CancerDecember 14th 2020
Dr. Pusztai on Evolution of Treatment for HER2+ Breast CancerSeptember 19th 2016
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
4
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
5